Insider Selling: BioLife Solutions (NASDAQ:BLFS) CEO Sells 37,795 Shares of Stock

Key Points

• BioLife Solutions CEO Greef Roderick De sold 37,795 shares of the company's stock for approximately $1.03 million, reducing his stake by 7.16% and maintaining ownership of 489,998 shares.
• The company's stock experienced a 0.5% increase, closing at $28.79, after having a trading volume of 267,911 shares compared to an average volume of 462,768 shares.
• BioLife Solutions reported a net loss of ($0.33) EPS for the last quarter, falling short of analyst estimates while exceeding revenue expectations with $25.42 million.

BioLife Solutions, Inc. (NASDAQ:BLFS - Get Free Report) CEO Greef Roderick De sold 37,795 shares of BioLife Solutions stock in a transaction on Wednesday, October 22nd. The stock was sold at an average price of $27.30, for a total transaction of $1,031,803.50. Following the sale, the chief executive officer directly owned 489,998 shares of the company's stock, valued at $13,376,945.40. This represents a 7.16% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link.

BioLife Solutions Stock Up 0.5%

NASDAQ BLFS traded up $0.13 on Friday, reaching $28.79. The company had a trading volume of 267,911 shares, compared to its average volume of 462,768. BioLife Solutions, Inc. has a 52 week low of $19.10 and a 52 week high of $29.62. The stock's 50 day moving average is $26.02 and its 200-day moving average is $23.62. The stock has a market cap of $1.38 billion, a price-to-earnings ratio of -239.90 and a beta of 1.95.

BioLife Solutions (NASDAQ:BLFS - Get Free Report) last issued its earnings results on Thursday, August 7th. The medical equipment provider reported ($0.33) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.02) by ($0.31). The company had revenue of $25.42 million for the quarter, compared to the consensus estimate of $23.71 million. BioLife Solutions had a positive return on equity of 0.16% and a negative net margin of 5.39%. BioLife Solutions has set its FY 2025 guidance at EPS. As a group, analysts forecast that BioLife Solutions, Inc. will post -0.3 EPS for the current year.

Hedge Funds Weigh In On BioLife Solutions

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Conestoga Capital Advisors LLC boosted its stake in BioLife Solutions by 16.1% in the 3rd quarter. Conestoga Capital Advisors LLC now owns 75,502 shares of the medical equipment provider's stock worth $1,926,000 after purchasing an additional 10,485 shares during the period. Summit Creek Advisors LLC acquired a new position in shares of BioLife Solutions during the 3rd quarter worth about $4,905,000. SG Americas Securities LLC acquired a new position in shares of BioLife Solutions during the 3rd quarter worth about $292,000. KLP Kapitalforvaltning AS boosted its stake in shares of BioLife Solutions by 34.8% during the 3rd quarter. KLP Kapitalforvaltning AS now owns 8,900 shares of the medical equipment provider's stock worth $227,000 after buying an additional 2,300 shares during the last quarter. Finally, Louisiana State Employees Retirement System increased its position in shares of BioLife Solutions by 2.9% in the third quarter. Louisiana State Employees Retirement System now owns 17,800 shares of the medical equipment provider's stock valued at $454,000 after acquiring an additional 500 shares during the last quarter. 93.24% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of research firms have issued reports on BLFS. HC Wainwright reissued a "buy" rating and issued a $32.00 target price (up from $30.00) on shares of BioLife Solutions in a research note on Friday, August 8th. Weiss Ratings restated a "sell (d-)" rating on shares of BioLife Solutions in a report on Friday. Zacks Research downgraded BioLife Solutions from a "strong-buy" rating to a "hold" rating in a report on Tuesday, October 7th. Finally, Stephens assumed coverage on BioLife Solutions in a report on Tuesday, July 22nd. They issued an "overweight" rating and a $30.00 price target for the company. Seven analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, BioLife Solutions presently has a consensus rating of "Moderate Buy" and a consensus price target of $31.29.

BioLife Solutions Company Profile

BioLife Solutions, Inc develops, manufactures, and markets bioproduction tools and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company's products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.